SION
NASDAQSionna Therapeutics Inc.
Sionna Therapeutics Inc. (SION) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. In the last 30 days Quantisnow tracked 2 wire items for SION, including 2 press releases and news items. The most recent was published Nov 2, 2026.
SION rankings
Financial highlights
Full financials- Net income, TTM
- -$97.38M
- Free cash flow, TTM
- -$76.21M
- Cash
- $63.32M
For the twelve months ended Jun 30, 2026, from SEC filings. Not investment advice.
News · 26 weeks50-90%
2026-05-102026-11-01
Mix2090d
- Analyst7(35%)
- Insider5(25%)
- SEC Filings3(15%)
- Other3(15%)
- Earnings2(10%)
Latest news
25 items- PRSionna Therapeutics to Participate in Upcoming November 2026 Investor ConferencesWALTHAM, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (NASDAQ:SION), a clinical-stage biopharmaceutical company on a mission to develop novel medicines for cystic fibrosis (CF), today announced that management will participate in fireside chats at the following upcoming investor events: Guggenheim's 3rd Annual Healthcare Innovation Conference fireside chat on Monday, November 9th, 2026, at 10:30 a.m. ET; andStifel’s 2026 Healthcare Conference fireside chat on Tuesday, November 10th, 2026, at 8:40 a.m. ET Live webcasts can be accessed in the ‘Investors’ section of Sionna’s website at https://investors.sionnatx.com. Replays will also be available following the events.
- PRSionna Therapeutics to Present Data at the 2026 North American Cystic Fibrosis ConferencePreviously disclosed post hoc PreciSION CF analyses of SION-719 support advancement of SION-451 + SION-2222 into the AscenSION CF Phase 2a proof-of-concept trial New preclinical data evaluating NBD1 stabilizers in combination with other CFTR modulators across F508del genotype groups demonstrated the potential of NBD1 stabilizer-based combinations to benefit a broad population of people with CF WALTHAM, Mass., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (NASDAQ:SION), a clinical-stage biopharmaceutical company on a mission to develop novel medicines for cystic fibrosis (CF), today announced data being presented at the 2026 North American Cystic Fibrosis Conference (NACFC)
- INSIDERDirector Ra Capital Management, L.P. sold $21,835,018 worth of shares (3,448,811 units at $6.33) (SEC Form 4)4 - Sionna Therapeutics, Inc. (0002036042) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Sionna Therapeutics Inc.SCHEDULE 13D/A - Sionna Therapeutics, Inc. (0002036042) (Subject)
- INSIDERCFO and CBO Ridloff Elena was granted 94,537 shares, increasing direct ownership by 245% to 133,069 units (SEC Form 4)4 - Sionna Therapeutics, Inc. (0002036042) (Issuer)
- INSIDERCMO and Head of R&D Mckee Charlotte was granted 100,000 shares, increasing direct ownership by 352% to 128,415 units (SEC Form 4)4 - Sionna Therapeutics, Inc. (0002036042) (Issuer)
- INSIDERCLO and Head of Program Mgmt. Fitzpatrick Jennifer was granted 56,265 shares (SEC Form 4)4 - Sionna Therapeutics, Inc. (0002036042) (Issuer)
- INSIDERPresident & CEO Cloonan Michael was granted 218,050 shares, increasing direct ownership by 40% to 765,393 units (SEC Form 4)4 - Sionna Therapeutics, Inc. (0002036042) (Issuer)
- SECSEC Form 144 filed by Sionna Therapeutics Inc.144 - Sionna Therapeutics, Inc. (0002036042) (Subject)
- SECSEC Form 8-K filed by Sionna Therapeutics Inc.8-K - Sionna Therapeutics, Inc. (0002036042) (Filer)
- PRSionna Therapeutics Announces Plans to Advance SION-451 + SION-2222 Dual Combination into Phase 2a Proof-of-Concept TrialPost hoc analyses of SION-719 PreciSION CF subset showed a mean placebo-adjusted sweat chloride reduction of up to -8.6 mmol/L consistent with NBD1 biological activity Dual combination Phase 2a trial expected to initiate in first quarter of 2027 46% workforce reduction and other cost-saving measures prioritize advancing the dual combination program and extend cash runway into the second half of 2029 Sionna to host conference call today at 4:30 p.m. ET WALTHAM, Mass., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (NASDAQ:SION), a clinical-stage biopharmaceutical company on a mission to develop novel medicines for cystic fibrosis (CF), today announced plans to advance SION
- ANALYSTSionna Therapeutics downgraded by BTIG ResearchBTIG Research downgraded Sionna Therapeutics from Buy to Neutral
- ANALYSTSionna Therapeutics downgraded by GuggenheimGuggenheim downgraded Sionna Therapeutics from Buy to Neutral
- ANALYSTSionna Therapeutics downgraded by CitizensCitizens downgraded Sionna Therapeutics from Mkt Outperform to Mkt Perform
- ANALYSTSionna Therapeutics upgraded by RBC Capital Mkts with a new price targetRBC Capital Mkts upgraded Sionna Therapeutics from Underperform to Sector Perform and set a new price target of $5.00
- ANALYSTSionna Therapeutics downgraded by Raymond JamesRaymond James downgraded Sionna Therapeutics from Strong Buy to Mkt Perform
- ANALYSTSionna Therapeutics downgraded by Wedbush with a new price targetWedbush downgraded Sionna Therapeutics from Outperform to Neutral and set a new price target of $5.00
- ANALYSTSionna Therapeutics downgraded by Stifel with a new price targetStifel downgraded Sionna Therapeutics from Buy to Hold and set a new price target of $7.00
- SECSEC Form 8-K filed by Sionna Therapeutics Inc.8-K - Sionna Therapeutics, Inc. (0002036042) (Filer)
- PRSionna Therapeutics Reports Topline Data from Two Development Programs in Cystic Fibrosis and Provides Corporate UpdateSION-719 Phase 2a proof-of-concept trial did not achieve key activity endpoint of sweat chloride reduction when added to standard of care; Company is not advancing SION-719 as an add-on to standard of care Potential confounders in SION-719 Phase 2a trial are being evaluated to inform next steps for the SION-451 dual combination clinical program Ended Q2 with approximately $268.3 million in cash and plans to take actions to preserve capital while evaluating next steps Sionna to host conference call today at 8:00 a.m. ET WALTHAM, Mass., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (NASDAQ:SION), a clinical-stage biopharmaceutical company on a mission to develop novel medic
- SECSEC Form 10-Q filed by Sionna Therapeutics Inc.10-Q - Sionna Therapeutics, Inc. (0002036042) (Filer)
- SECSionna Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition8-K - Sionna Therapeutics, Inc. (0002036042) (Filer)
- PRSionna Therapeutics Reports Second Quarter 2026 Financial ResultsPreciSION CF Phase 2a proof-of-concept trial evaluating NBD1 stabilizer SION-719 as an add-on to standard of care is on track for topline data summer of 2026 Phase 1 trial evaluating NBD1 stabilizer SION-451 in proprietary dual combinations with SION-2222 and with SION-109 also is on track for topline data summer of 2026 Maintained strong cash position with $268.3 million in cash and cash equivalents, expected to fund operations into 2028 WALTHAM, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (NASDAQ:SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) today reported financial results
- INSIDERDirector Thompson Peter A. sold $3,854,281 worth of shares (85,918 units at $44.86) as part of a pre-agreed trading plan (SEC Form 4)4 - Sionna Therapeutics, Inc. (0002036042) (Issuer)
- INSIDERDirector Orbimed Advisors Llc sold $3,854,281 worth of shares (85,918 units at $44.86) as part of a pre-agreed trading plan (SEC Form 4)4 - Sionna Therapeutics, Inc. (0002036042) (Issuer)
SION FAQ
9 questionsWhat is the latest news on SION?
In the last 30 days Quantisnow tracked 2 wire items for SION: 2 press releases and news items. The most recent was published on November 2, 2026.Is SION profitable?
No. Sionna Therapeutics Inc. reported a net loss of $97.38M for the twelve months ended Jun 30, 2026.How much cash and debt does SION have?
Sionna Therapeutics Inc. reported $63.32M in cash and cash equivalents on its most recent balance sheet in SEC filings.Where does SION stock trade?
Sionna Therapeutics Inc. (SION) is listed on NASDAQ.What sector and industry is SION in?
Sionna Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Sionna Therapeutics Inc. go public?
Sionna Therapeutics Inc. (SION) completed its IPO in 2025.What are analysts saying about SION?
Across the last 8 analyst actions on Sionna Therapeutics Inc., there was 1 upgrade and 6 downgrades. The most recent action was from BTIG Research: Neutral on 2026-08-10.What companies are similar to SION?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare SION side-by-side with any of them on Quantisnow.How can I track SION on Quantisnow?
Quantisnow aggregates Sionna Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SION to receive live email and push alerts on every new disclosure.